Lineage Cell Therapeutics Inc
LCTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$251.79M
Close$
$-1.33
225.7% downside
Current Fair Value
225.7% downsideOvervalued by 225.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $251.79 Million |
|---|---|
| Enterprise Value | $218.41 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.28 |
| Beta | 1.55 |
| Outstanding Shares | 249,499,000 |
Return
| Return on Equity | -53.95% |
|---|---|
| Return on Assets | -30.37% |
| Return on Invested Capital | -16.68% |
Valuation & Multiples
| P/E Ratio | -7.2 |
|---|---|
| PEG | 6.87 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 16.69 |
| Enterprise Value to EBIT | -13.33 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$1.84 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$1.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2023▲ 1.29% |
|---|---|
| Total Calls | 102,800▼ 10.69% |
| Total Puts | 20,800▼ 4.59% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 47.02%▲ 1.44% |
|---|---|
| Total Invested | $153.61M▼ 12.95% |
| Investors Holding | 136▲ 4.00% |
ESG Score
No data
About Lineage Cell Therapeutics Inc
CEO: Brian Culley